Jennifer A Tuazon

Grants

Grants per year 2006 2006 2007 2011 2013 2015 2017 2018 2019 2022 2025

• 2 Active
• 9 Finished

Grants per year

Search results

• Active

  Prot #402-C-1803: An Extended Access Program To Assess Long Term Safety Of Bardoxolone Methyl In Patients With Chronic Kidney Disease (EAGLE)

  Tuazon, J. A.

  Reata Pharmaceuticals, Inc.

  3/3/22 → 3/3/25

  Project: Research project

• Protocol 402-C-1808: A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease

  Tuazon, J. A.

  Reata Pharmaceuticals, Inc.

  7/24/19 → 7/24/25

  Project: Research project

• Finished

  Prot#CV185-450:RENal hemodialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial

  Tuazon, J. A.

  Frenova Renal Research, Bristol-Myers Squibb Company

  8/27/18 → 8/27/21

  Project: Research project

• Prot# ST-001: A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-Controlled, Clinical Trial

  Tuazon, J. A.

  Hope Medical Enterprises, Inc.

  11/27/17 → 11/27/20

  Project: Research project

• Prot# RLY5016-207: A Randomized, Double-Blind, Placebo-controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chronic Kidney Disease: Evaluation of Saf

  Tuazon, J. A.

  Relypsa, Inc.

  4/24/17 → 4/24/20

  Project: Research project

• Prot #OPC-41061/156-13-211: A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease

  Tuazon, J. A.

  Quintiles, Inc., Otsuka Pharmaceutical Development & Commericalization, Inc.

  2/1/15 → 7/31/19

  Project: Research project

• Variation in the Aquaretic Efficacy of Tolvaptan in Healthy Adults

  Tuazon, J. A.

  Otsuka Pharmaceutical Development & Commericalization, Inc.

  9/1/13 → 12/31/15

  Project: Research project

• Prot# 156-10-292: An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hosptitalized with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Im

  Tuazon, J. A.

  Mapi USA, Inc., Otsuka America Pharmaceutical, Inc.

  3/15/11 → 3/15/14

  Project: Research project

• Protocol No. 156-08-271: Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  Tuazon, J. A.

  Covance Inc., Otsuka Pharmaceutical Development & Commericalization, Inc.

  2/16/11 → 2/16/17

  Project: Research project

• Prot# 156-04-251: A Phase 3, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Arm Trial to Determine Long-Term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease

  Batlle, D., Tuazon, J. A. & Ghossein, C.

  Parexel, Otsuka Maryland Research Institute, Inc.

  9/4/07 → 9/4/10

  Project: Research project

• Prot# 20050182: EVOLVE: Evaluation of Cinacalcet HCI Therapy to Lower CardioVascular Events

  Batlle, D., Tuazon, J. A. & Schlueter, W. A.

  Fresenius Medical Care North America, Amgen, Inc.

  11/3/06 → 5/1/12

  Project: Research project